Skip to main content
Top
Published in: Globalization and Health 1/2018

Open Access 01-12-2018 | Research

Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences

Authors: H. Hilda Ampadu, Jarno Hoekman, Daniel Arhinful, Marilyn Amoama-Dapaah, Hubert G. M. Leufkens, Alex N. O. Dodoo

Published in: Globalization and Health | Issue 1/2018

Login to get access

Abstract

Background

National pharmacovigilance centres (national centres) are gradually gaining visibility as part of the healthcare delivery system in Africa. As does happen in high-income countries, it is assumed that national centres can play a central coordinating role in their national pharmacovigilance (PV) systems. However, there are no studies that have investigated whether national centres in Africa have sufficient organizational capacity to deliver on this mandate and previous studies have reported challenges such as lack of funding, political will and adequate human resources.
We conducted interviews with strategic leaders in national centres in 18 African countries, to examine how they link the capacity of their organization to the outcomes of activities coordinated by their centres. Strategic leaders were asked to describe three situations in which activities conducted by their centre were deemed successful and unsuccessful. We analyzed these experiences for common themes and examined whether strategic leaders attributed particular types of resources and relationships with stakeholders to successful or unsuccessful activities.

Results

We found that strategic leaders most often attributed successful experiences to the acquisition of political (e.g. legal mandate) or technical (e.g. active surveillance database) resources, while unsuccessful experiences were often attributed to the lack of financial and human resources. Stakeholders that were most often mentioned in association with successful experiences were national government and development partners, whereas national government and public health programmes (PHPs) were often mentioned in unsuccessful experiences. All 18 centres, regardless of maturity of their PV systems had similar challenges.

Conclusions

The study concludes that national centres in Africa are faced with 3 core challenges: (1) over-reliance on development partners, (2) seeming indifference of national governments to provide support after national centres have gained membership of the World Health Organization (WHO) Programme for International Drug Monitoring (PIDM) and (3) engaging public health programmes in a sustainable way.
Appendix
Available only for authorised users
Literature
1.
go back to reference Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689–703.PubMedCrossRef Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689–703.PubMedCrossRef
2.
go back to reference Lu Y, Hernandez P, Abegunde D, Edejer T. The world medicines situation 2011 - medicine expenditures. World Health Organ. 2011;3:1–34. Lu Y, Hernandez P, Abegunde D, Edejer T. The world medicines situation 2011 - medicine expenditures. World Health Organ. 2011;3:1–34.
3.
go back to reference Janarthanan VV, Ramakrishnan G, Krishnamurthy S, Sahar AI. Pharmacist as pharmacovigilance practitioner. Indian J Pharm Pract. 2015;8(1):2–6.CrossRef Janarthanan VV, Ramakrishnan G, Krishnamurthy S, Sahar AI. Pharmacist as pharmacovigilance practitioner. Indian J Pharm Pract. 2015;8(1):2–6.CrossRef
4.
go back to reference Venulet J, Helling-Borda M. WHOs international drug monitoring the formative years, 19681975: preparatory, pilot and early operational phases. Drug Saf. 2010;33(7):1–23.CrossRef Venulet J, Helling-Borda M. WHOs international drug monitoring the formative years, 19681975: preparatory, pilot and early operational phases. Drug Saf. 2010;33(7):1–23.CrossRef
9.
go back to reference Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements. Int J Health Policy Manag. 2015;4(5):295–305.PubMedPubMedCentralCrossRef Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements. Int J Health Policy Manag. 2015;4(5):295–305.PubMedPubMedCentralCrossRef
10.
go back to reference Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449–60.PubMedCrossRef Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449–60.PubMedCrossRef
11.
go back to reference Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.PubMedPubMedCentralCrossRef Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.PubMedPubMedCentralCrossRef
12.
go back to reference Stergachis A, Bartlein RJK, Dodoo A, Nwokike J, Kachur SP. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President’s Malaria Initiative proposals. Malar J. 2010;9(1):148.PubMedPubMedCentralCrossRef Stergachis A, Bartlein RJK, Dodoo A, Nwokike J, Kachur SP. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President’s Malaria Initiative proposals. Malar J. 2010;9(1):148.PubMedPubMedCentralCrossRef
13.
go back to reference Schäublin M. Pharmacovigiance: the spontaneous reporting system in Switzerland. Ther Umsch. 2015;72(11/12):743–8.PubMedCrossRef Schäublin M. Pharmacovigiance: the spontaneous reporting system in Switzerland. Ther Umsch. 2015;72(11/12):743–8.PubMedCrossRef
20.
go back to reference Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, Owusu-Agyei S, et al. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;15(1):1–10.CrossRef Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, Owusu-Agyei S, et al. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;15(1):1–10.CrossRef
23.
go back to reference Moscou K, Kohler JC. Matching safety to access: global actors and pharmacogovernance in Kenya- a case study. Glob Health. 2017;13(1):20.CrossRef Moscou K, Kohler JC. Matching safety to access: global actors and pharmacogovernance in Kenya- a case study. Glob Health. 2017;13(1):20.CrossRef
24.
go back to reference Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39(4):335–45.PubMedPubMedCentralCrossRef Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39(4):335–45.PubMedPubMedCentralCrossRef
25.
go back to reference Dodoo A, Pal SN, Falzon D, Xueref S. Pharmacovigilance for tuberculosis does not feature prominently in grant applications to the Global Fund to Fight AIDS, tuberculosis and malaria. Drug Saf. 2010;33:924. Dodoo A, Pal SN, Falzon D, Xueref S. Pharmacovigilance for tuberculosis does not feature prominently in grant applications to the Global Fund to Fight AIDS, tuberculosis and malaria. Drug Saf. 2010;33:924.
32.
go back to reference Dodoo ANO. Active safety surveillance in Africa: pragmatism and agility. Drug Saf. 2018;41:731–3.PubMedCrossRef Dodoo ANO. Active safety surveillance in Africa: pragmatism and agility. Drug Saf. 2018;41:731–3.PubMedCrossRef
Metadata
Title
Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences
Authors
H. Hilda Ampadu
Jarno Hoekman
Daniel Arhinful
Marilyn Amoama-Dapaah
Hubert G. M. Leufkens
Alex N. O. Dodoo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2018
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-018-0431-0

Other articles of this Issue 1/2018

Globalization and Health 1/2018 Go to the issue